drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Autologous anti-mesothelin CAR T-cell therapy; patient T cells are engineered to express a CAR targeting mesothelin (MSLN) to induce T-cell activation and cytotoxic killing of MSLN-positive tumor cells.
nci_thesaurus_concept_id
C200297
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MSLN CAR-T cells UCLM802 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds mesothelin (MSLN) on tumor cells; CAR engagement triggers T‑cell activation and effector functions (e.g., perforin/granzyme release and cytokine production) resulting in selective killing of MSLN‑positive tumor cells.
drug_name
UCLM802
nct_id_drug_ref
NCT05775666